ALLO - Heron defended despite plunge after FDA approval Aurora earns mixed reactions after Q3 results; and more in today's analyst action

Fate's early stage data look promising: JefferiesFate Therapeutics (FATE) shares shed ~1.4% after the company announced data from an early stage leukemia trial for its natural killer ((NK)) cell programs.Fate has lost ~21.3% in the year so far and noting that data looked promising and have de-risked the company’s NK cell platform, Jefferies analyst Michael Yee with a buy rating urges investors to make use of the decline. Price target of $145.00 per share indicates a ~102.8% premium.In February, Bank of America initiated the coverage on Fate with a buy rating. Its NK-cell platform has advantages such as multiple dosing and less severe/ costly side effects, the analysts argued.Guggenheim defends Heron despite a narrower label for ZYNRELEFHeron Therapeutics (HRTX) plunged ~10.8% yesterday notwithstanding the FDA approval granted for the company’s postoperative painkiller ZYNRELEF (bupivacaine and meloxicam).Heron had sought a broader label for the drug, and the approval has come with

For further details see:

Heron defended despite plunge after FDA approval, Aurora earns mixed reactions after Q3 results; and more in today's analyst action